244 related articles for article (PubMed ID: 32559143)
1. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
L Gemmill JA; Sher A
Cancer Invest; 2020 Jul; 38(6):365-371. PubMed ID: 32559143
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
4. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
Kanai O; Kim YH; Demura Y; Kanai M; Ito T; Fujita K; Yoshida H; Akai M; Mio T; Hirai T
Thorac Cancer; 2018 Jul; 9(7):847-855. PubMed ID: 29782069
[TBL] [Abstract][Full Text] [Related]
7. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
Delaunay M; Cadranel J; Lusque A; Meyer N; Gounant V; Moro-Sibilot D; Michot JM; Raimbourg J; Girard N; Guisier F; Planchard D; Metivier AC; Tomasini P; Dansin E; Pérol M; Campana M; Gautschi O; Früh M; Fumet JD; Audigier-Valette C; Couraud S; Dalle S; Leccia MT; Jaffro M; Collot S; Prévot G; Milia J; Mazieres J
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28798088
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
9. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
Tao H; Li F; Li R; Han X; Hu Y
Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
14. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
[TBL] [Abstract][Full Text] [Related]
15. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
Sławiński G; Wrona A; Dąbrowska-Kugacka A; Raczak G; Lewicka E
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003425
[TBL] [Abstract][Full Text] [Related]
17. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
Shibaki R; Murakami S; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Kusumoto M; Yamamoto N; Ohe Y
Cancer Immunol Immunother; 2020 Jan; 69(1):15-22. PubMed ID: 31745589
[TBL] [Abstract][Full Text] [Related]
18. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
20. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
